l||||l|||||||||||||||||||||||||||||||l||||||||l||||||||||||||||||||||||||l| USO0H002260H
(19) United States (12) Statutory Invention Registration (10) Reg. N0.2 Toleikis (54)
(43) Published:
STENTS COMBINED WITH PACLITAXEL
2005/0181977 A1
DERIVATIVES
(75)
Inventor:
Philip M. Toleikis, Vancouver (CA)
8/2005 Hunter et al. ................ .. 514/2
W0
WO 91/12779
9/ 199 1
OTHER PUBLICATIONS Fleischer, David E., et al., “A NeW Coated SelfiExpanding Metal Stent for Malignant Esophageal Strictures, ” Gas Zroinleslinal Endoscopy 38(4):4944196, 1992. Stierle, Andrea, et al., “Taxol and Taxane Production by Taxomyces andreanae, an Endophytic Fungus of Paci?c
(21) APPI'NO'Z 11/357’368 (22) Filed; Feb_ 17, 2006 Related US. Application Data Provisional application No. 60/653,844, ?led on Feb. 17,
2005' (51) Int_ CL A611?‘ 2/00
Jul. 5, 2011
FOREIGN PATENT DOCUMENTS
(73) Assignee: Angiotech International AG, Zug (CH)
(60)
US H2260 H
YeW, ” Science 260Z214*216, Apr. 9, 1993.
Wani, M.C., et al., “Plant Antitumor Agents. V1. The Isola tion and Structure of Taxol, a Novel Antileukemic and Anti tumor Agent from Taxus brevifolia, ” Journal of the Ameri
(200601)
can Chemical Society, 93(9):2325*2327, May 5, 1971. (52)
US. Cl.
..................................................... ..
(58)
Field Of Classi?cation Search ................. .. 424/423
Pnmary ExammeriMlchene Clement
See application ?le for complete search history.
(57)
(56)
424/423
References Cited
.
.
.
ABSTRACT
Stents are used in combination With a paclitaxel derivative in order to inhibit scarring that may otherwise occur When the
us PATENT DOCUMENTS
implant is placed Within an animal. Suitable implants
4,876,399 A
10/1989 Holton et a1‘ _____________ __ 568/817
include vascular stents, esophageal stents, tracheal or bron
4,942,184 A 5,352,806 A
7/1990 HaugWitZ et al. ......... .. 514/449 10/1994 Gunawardana et a1. 549/510
0111211 Stents, gastrointestinal Stents, genital-urinary Stents, nasal and sinus stents, and ENT stems.
5,440,056 A 5,468,769
A
5,616,608 A 5,716,981 A 5,733,925
A
6,074,659 A 6,171,609 B1 6,268,390 B1
8/1995 11/1995
Klein et a1. ............... .. 549/510 Klein et a1.
.....
. . . ..
4/1997 Kinsella et a1. . 2/1998 Hunter et a1. 3/1998
KunZ et a1.
6/2000 1/2001 7/2001
KllIlZ et a1~ - - - - KunZ ......... .. KunZ ......... ..
.....
514/449
514/449 514/449 . . . ..
_
_
26 Clam“, 19 Drawlng sheets
514/449
- - - ~~ 424/423
A statutory invention registration is not a patent. It has
424/422
the defensive attributes of a patent but does not have the enforceable attributes of a patent. No article or adver tisement or the like may use the term patent, or any term
6,306,421 6,403,635 B1
10/2001 6/2002 Kinsella KunZ et al. et a1. .
5 14/449
6,491,938 B2
12/2002 KunZ et al.
424/423
suggestive of a patent, When referring to a statutory
_____
_ _ _ __ 514/411
invention registration. For more speci?c information on
___________
_ _ _ __ 514/449
6,515,009 B1 6,515,016
B2
6,599,928 B2
2/2003
KunZ et a1,
2/2003
Hunter
7/2003 KunZ et al. ............... .. 514/411
the rights associated With a statutory invention registra
tion see 35 U.S.C. 157.
US. Patent
Jul. 5, 2011
US H2260 H
Sheet 1 0119
cEEmo51=mn5 ~.ME
uEiwHoS2t3Ea:
US. Patent
Jul. 5, 2011
US H2260 H
Sheet 2 0f 19
325Em.03:5. N
.ME
2U6i3o.:62t0a5
US. Patent
Jul. 5, 2011
US H2260 H
Sheet 3 0f 19
80982.m=0%5x.?8:0
cnm2“BEo3>umax:-t=E3u
m.ME
$965S59.w2.63
US. Patent
Jul. 5, 2011
Sheet 5 0f 19
US H2260 H
2T2xh+ 20;:xh.+ 2W2xh+
.MEE.
US. Patent
Jul. 5, 2011
Sheet 6 0f 19
US H2260 H
PCMocn?elfxmon,
4CFig.
US. Patent
Jul. 5, 2011
Sheet 7 0f 19
US H2260 H
/
‘I’ Q a U
'
5W
COLLA GEN/15E
SIROMEL YSIN
GAPDH
Fig. 4D
US. Patent
Jul. 5, 2011
Sheet 8 0f 19
US H2260 H
Ly 290181
GAPDH
11-1 (ng/ml.)
0
‘2o.
20'
Drug (M)
o
o
140*? 10"‘10'5 10-‘
Fig. 5A
v20 _ '20
20
US. Patent
Jul. 5, 2011
Sheet 9 0f 19
US H2260 H
2-Methyl-2,4-Pentanediol (Hexylene Glycol)
Collnganase
GAPQH
IL-‘r (ng/mL)
u
20
20
Drug (u)
o
u
10*? 10''‘ W5 10-‘
Fig. 5B
2o
20
20
US. Patent
Jul. 5, 2011
US H2260 H
Sheet 10 0f 19
Deuierium Oxide 99.9oiomXD
Collagenase
2o
20
0
10-7 ‘0-6 10-5 10-‘
Fig. 5C
20
20
2o
US. Patent
Jul. 5, 2011
US H2260 H
Sheet 11 0119
Glycine Ethyl Ester
.
I
Q
"0'.
Collagenase
.
'Q 3
.
’.
‘r
.I
u
I
O
.
.
'
33, GAL)’. '1 J
I
1....‘
a.’ '0
v.0!
I
v I
GAPDH
lL-I (ng/mL)
Drug (M)
0 0
20
20
o
10''? 1o"6 10“5 10-4
Fig. 51) _
20
20
20
US. Patent
Jul. 5, 2011
US H2260 H
Sheet 13 0f 19
Tubercidin
c.M.mg9m8
\L—-! (ng/mL)
o
20
20
Drug (M)
0
0
10'‘7 10"5 10's 10"‘
Fig. 5F
20
20
20
US. Patent
Jul. 5, 2011
Sheet 14 0f 19
Aluminum Fluoride
wI.In0.anm
Fig. 5G
US H2260 H
US. Patent
Jul. 5, 2011
Sheet 15 0f 19
Epoihilone B
Callagenasa
Fig. 5H
US H2260 H
U.S. Patent
Jul. 5, 2011
Sheet 16 0119
US H2260 H
~
~
_
u 13
w G]l|
18
m [Fm wLOW U
%
3dFR:
_ _ .O _
iczea?m
m..ME
US. Patent
Jul. 5, 2011
i
2
:2.
Sheet 17 0119
3l:08?i .52T?SE6Ex:08m9z:25o3;m05
US H2260 H
R.ME
US. Patent
Jul. 5, 2011
88F. _
_
_ .
+ a
lg“.
Sheet 18 0f 19
?m25.89xw:3uz:502SmQa.5
US H2260 H
%.ME
US. Patent
Jul. 5, 2011
Sheet 19 0119
US H2260 H
a.mi e2. uomqmul %
